## NEW UNITED STATES UTILITY PATENT APPLICATION TRANSMITTAL

Atty. Docket No.: 4231/2055C

U.S.	CERTIFICATE OF MAILING UNDER 37 CFR 1.10						
I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, Express Mail Label No. EV242756459US on this date, March 25, 2004, postage prepaid, in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  Amy Decloux							
			Na	ame of Person Mailing Paper		2 4	
	Signature of Person Mailing Paper						
Mail Stop Patent Application Commissioner for Patents P.O. Box 1450					17510 U.S. 1 10/80967		
Alexani	Alexandria, VA 22313-1450  Enclosed herewith is a new patent application of:						
	First Named Inventor (or application identifier): Choong-Chin Liew						
	Title of Invention:  A Method for the Detection of Osteoarthritis Related Gene Transcr in Blood						
Type: New							
	$\boxtimes$	Continuation of: Continuation-in-Part of:	(Serial No. not yet assigned) Attorney Docket No. 4231/2055B, Filed March 12, 2004				
		Divisional of:				_	
	which is hereby incorporated by reference in is entirety into the application filed herewith;						
	and in	l includes the following papers:					
1.	$\boxtimes$	Specification 273 pages	ecification 273 pages (including specification, claims, abstract)/48 claims (13 independent)				
2.		Declaration/Power of Attorney is:  Executed Unexecuted Executed copy from Parent Application NOT included, but deferred under 37 C.F.R. § 1.53(f).					
3.	$\boxtimes$	35 Distinct sheets of  Formal  Informal Drawings					
4.	$\boxtimes$	Application Data Sheet					
5		Preliminary Amendment.					
6.		Information Disclosure Statement  Form 1449  A copy of each cited prior art reference (as necessary)					
7.		Assignment with Recordation Cover Sheet.					
8.		Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):					
		Country	Application Number		Date of Filing (day, month, year)		
		US	60/271,955		28 February, 2001		
		US	60/305,340		13 July, 2001		
US		60/275,017		12 March, 2001			
·	US		60/115,125		6 January, 1999		
9.	$\boxtimes$	Priority is hereby claim	claimed under 35 U.S.C. § 120 based upon the following application(s):				
Application Number				Date of Filing (day, month, year)			
Not Yet Assigned (Atty. Docket No. 4231/2055B)			. 4231/2055B)	March 12, 2004			

# NEW UNITED STATES UTILITY PATENT APPLICATION TRANSMITTAL

Atty. Docket No.: 4231/2055C

10/601,518			20 June, 2003				
10/268,730			9 October, 2002				
	10/085,783			28 Febru	ary, 2002		
	09/477,148			4 January, 2000			
10.		Priority is hereby claimed under 35 U.S.C. § 121 based upon the following application(s):					
		Application Number	Date of Filing (day, month, year)				
The above applications from which priority is claimed are hereby incorporated in their entirety into the application filed herewith.							
11.		Priority document(s).					
12.		Microfiche Computer Program (Appendix).					
13.	Nucleotide and/or Amino Acid Sequence Submission.  Computer Readable Copy.  Paper Copy (identical to computer copy).  Statement verifying identity of above copies.						
14.	$\boxtimes$	Request for Non-Publication and Certification under 35 USC 122 (b)(2)(B)(i)					
15.	_						
16. Calculation of Fees:							
		FEES FOR	TOTAL CLAIMS	EXCESS CLAIMS	FEE	AMOUNT DUE	
Basic I	Filing Fee	e (37 C.F.R. § 1.16(a))	<u> </u>	<u> </u>		\$770.00	
Total C	Claims in	Excess of 20 (37 C.F.R. § 1.16(c))	234	214	\$18.00	3,852.00	
Indepe	ndent Cla	aims in Excess of 3 (37 C.F.R. § 1.16(b))	13	10	\$86.00	860.00	
		dent Claims (37 C.F.R. § 1.16(d))	YES \$290.00			290.00	
		g Fee Due				\$5,772.00	
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)  MULTIPLY BY 0.50				\$2,886.00			
		IG FEE DUE				\$2,886.00	
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))			0	0 \$40.00			
GRAN	GRAND TOTAL DUE \$2,886.00						
17.	17. PAYMENT is:  The Commissioner is hereby authorized to charge any fees to Deposit Account 16-0085, Ref. 4231/2055C.						
		not included, but deferred under 37 C.F.R. §	1.53(f).				

# NEW UNITED STATES UTILITY PATENT APPLICATION TRANSMITTAL

Atty. Docket No.: 4231/2055C

18.	All correspondence for the attached application should be directed to:  Kathleen Williams  Customer Number 29933  111 Huntington Avenue  Boston, MA 02199-7613			
19.	Other:			
	Respectfully submitted,			
Date:	3/25/04 By: for Wathlean Willians			
	Name: Kathleen Williams			
	Registration No.: 34 380			

Atty. Docket No.:

4231/2055C

**PATENT** 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Choong-Chin Liew

Serial No.:

Not Yet Assigned

Filed:

March 25, 2004

Entitled:

A Method for the Detection of Osteoarthritis

Related Gene Transcripts in Blood

#### **CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, Express Mail Label No. EV242756459US on this date, March 25, 2004, postage prepaid, in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Amy Decloux

Name of Person Mailing Paper

Mail Stop Patent Application **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

### TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

- 1. New Patent Application Transmittal;
- 2. Patent Application, (273pages);
- 3. Thirty-Five (35) sheets of informal drawings of Figs 1 - 35;
- 4. **Application Data Sheet:**
- Non-Pub Request (Request for Certification Under 35 U.S.C. 122(b)(2)(B)(i)); 5.
- Two (2) CD-ROMs (called Tables Copy 1, Tables Copy 2) in the following 6. format:

Machine Format: IBM-PC

Operating System: MS-Windows Files Contained: See Chart Below

Size: 6,395,367kb

Date of Creation: March 11, 2004

and containing Tables 2 - 4. The content of each CD-ROM is identical and is as shown on the following chart:

Attorney Docket No.: 4231/2055C Filed: March 25, 2004

	<b>TABLE</b>	DESCRIPTION	SIZE	CREATED	Text File Name
1	2	multi-gene comparison	360,434	3/11/2004	TABLE2.TXT
2	3A	GLF 8 - hypertension	135,839	3/11/2004	TABLE3A.TXT
3	3AA	GLF 29 - asthma	35,161	3/11/2004	TABLE3AA.TXT
4	3AB	multi	29,014	3/11/2004	TABLE3AB.TXT
5	3AC	GL MDS vs. schizo	108,209	3/11/2004	TABLE3AC.TXT
6	3AD	steroid differential	62,510	3/11/2004	TABLE3AD.TXT
7	3B	GLF 9 - obesity	144,119	3/11/2004	TABLE3B.TXT
8	3C	GLF 10 - allergies	94,501	3/11/2004	TABLE3C.TXT
9	3D	GLF 11 - steroids	92,750	3/11/2004	TABLE3D.TXT
10	3E	GLF 12 - hypertension	305,305	3/11/2004	TABLE3E.TXT
11	3F	GLF 13 - obesity	175,793	3/11/2004	TABLE3F.TXT
12	3G	GLF 14 - diabetes	141,847	3/11/2004	TABLE3G.TXT
13	3H	GLF 15 - hyperlipidemia	161,123	3/11/2004	TABLE3H.TXT
14	31	GLF 16 - lung	90,098	3/11/2004	TABLE3I.TXT
15	3J	GLF 17 - bladder	1,122,034	3/11/2004	TABLE3J.TXT
16	3K	GLF 18 - bladder	935,348	3/11/2004	TABLE3K.TXT
17	3L	GLF 19 - Coronary Art Dis.	242,266	3/11/2004	TABLE3L.TXT
18	3M	GLF 20 - rheumarth	319,966	3/11/2004	TABLE3M.TXT
19	3N	GLF 21 - depression	148,695	3/11/2004	TABLE3N.TXT
20	30	GLF 22 - rheumarth	48,245	3/11/2004	TABLE3O.TXT
21	3P	GLF hypertension 577 only	83,044	3/11/2004	TABLE3P.TXT
22	3Q	GLF OA hypertension shared	32,173	3/11/2004	TABLE3Q.TXT
23	3R	GL obesity 519	77,355	3/11/2004	TABLE3R.TXT
24	3S	GL obesity shared 152	23,788	3/11/2004	TABLE3S.TXT
25	3T	GL allergy specific	38,706	3/11/2004	TABLE3T.TXT
26	3U	GL allergy OA shared 241	34,590	3/11/2004	TABLE3U.TXT
27	3V	GL steroid 362	53,395	3/11/2004	TABLE3V.TXT
28	3W	GL OA steroid shared	30,469	3/11/2004	TABLE3W.TXT
29	3X	GLF 26 - liver cancer	419,159	3/11/2004	TABLE3X.TXT
30	3Y	GLF 27 - schizophrenia	547,026	3/11/2004	TABLE3Y.TXT
31	3Z	GLF 28 - chagas	187,640	3/11/2004	TABLE3Z.TXT
32	4	sequence listing	114,765	3/11/2004	TABLE4.TXT

Attorney Docket No.: 4231/2055C

Filed: March 25, 2004

### 7. Return Post Card.

Pursuant to 37 C.F.R. § 1.27, Applicant claims small entity status.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 4231/2055C. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: \_\_\_3-25-04

Name: Kathleen Williams Registration No.: 34,380 Customer No.: 29933 Palmer & Dodge LLP

any Delonie 54849 Signing for Hathlen Williams

111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

Express Mail Label Number: EV242756459US

Date of Deposit: March 25, 2004

## REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)

First Named Inventor Choong-Chin Liew

Title: A Method for the Detection of Osteoarthritis Related Gene Transcripts in Blood

Attorney Docket Number: 4231/2055C

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b)

March 25, 2004

Date

Signature Signature

Kathleen Williams

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant must notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).